Get the Stockscreener App
186.42
4.68%
8.34
After Hours:
185.29
-1.13
-0.61%
Praxis Precision Medicines Inc stock is traded at $186.42, with a volume of 868.03K.
It is up +4.68% in the last 24 hours and up +254.95% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$178.08
Open:
$178.08
24h Volume:
868.03K
Relative Volume:
1.10
Market Cap:
$3.92B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-20.33
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+10.82%
1M Performance:
+254.95%
6M Performance:
+402.48%
1Y Performance:
+142.48%
1-Day Range:
$175.79
$197.55
1-Week Range:
$160.38
$197.55
52-Week Range:
$26.70
$206.71
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
186.42 | 4.45B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
How institutional buying supports Praxis Precision Medicines Inc. stock2025 Trading Volume Trends & Accurate Trade Setup Notifications - newser.com
How analysts rate Praxis Precision Medicines Inc. stock todayQuarterly Performance Summary & Reliable Price Breakout Signals - newser.com
Published on: 2025-11-15 06:25:23 - newser.com
Using fundamentals and technicals on Praxis Precision Medicines Inc.2025 Winners & Losers & Daily Profit Focused Screening - newser.com
Is Praxis Precision Medicines Inc. stock a contrarian buy2025 Sector Review & Real-Time Market Sentiment Reports - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Using Python tools to backtest Praxis Precision Medicines Inc. strategiesMarket Growth Summary & Weekly Setup with High ROI Potential - newser.com
What valuation multiples suggest for Praxis Precision Medicines Inc. stockWeekly Risk Summary & Smart Allocation Stock Reports - newser.com
PRAX: HC Wainwright & Co. Raises Price Target to $258 | PRAX Sto - GuruFocus
Published on: 2025-11-12 17:26:58 - newser.com
Published on: 2025-11-12 08:52:54 - newser.com
How Praxis Precision Medicines Inc. stock valuations compare to rivalsWeekly Earnings Recap & Community Verified Trade Signals - newser.com
(PRAX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Published on: 2025-11-10 01:11:09 - newser.com
Published on: 2025-11-09 22:42:30 - newser.com
Praxis Precision Medicines Reports Q3 2025 Financial Results - MSN
Published on: 2025-11-08 04:02:56 - newser.com
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $270 From $280, Maintains Buy Rating - MarketScreener
Praxis Precision Medicines (PRAX) Is Up After Positive Ulixacaltamide Trial and FDA Alignment on RelutrigineHas the Investment Thesis Gained New Momentum? - Sahm
Does Praxis Precision Medicines Inc. qualify in momentum factor screeningTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating - MSN
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline - Investing.com Canada
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline By Investing.com - Investing.com South Africa
Wedbush Raises Price Target on Praxis Precision Medicines to $77 From $73, Keeps Underperform Rating - MarketScreener
PRAX: Wedbush Raises Price Target While Maintaining Underperform Rating | PRAX Stock News - GuruFocus
Praxis Precision announces inducement grants under Nasdaq lsiting rule - TipRanks
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines (NASDAQ: PRAX) grants 6,876 RSUs under 2024 Inducement Plan - Stock Titan
Is a relief rally coming for Praxis Precision Medicines Inc. holders2025 Market WrapUp & AI Based Buy and Sell Signals - newser.com
Praxis Precision Medicines, Inc.Common Stock (NQ: PRAX - Markets Financial Content
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beat2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):